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Xpert MTB/RIF (Cepheid, https://www.cepheid.com) is a cartridge-based nucleic amplification 
assay for use with Cepheid’s GeneXpert diagnostic 
instrument systems that detects both Mycobacterium 
tuberculosis complex (MTB) and resistance to rifampin 
(RIF). In 2010, the World Health Organization en-
dorsed Xpert MTB/RIF for laboratory detection of 
tuberculosis (TB) (1), signaling a sea change for di-
agnosing TB. Xpert MTB/RIF increased sensitivity 
over microscopy and its ability to simultaneously de-
tect rifampin resistance led to its rapid adoption in 
low- and middle-income countries. Within the first 5 
years, 23 million cartridges were procured at the ne-
gotiated price of $9.98/each (P. Jacon, Cepheid, pers. 
comm., email, April 2020). In 2017, the Cepheid Xpert 
MTB/RIF Ultra assay (Ultra) was released for use on 
GeneXpert instruments and results determined to be 
comparable to those from the Xpert MTB/RIF assay, 
with an even lower limit for detection (1). 
Coronavirus disease (COVID-19) is severely dis-
rupting health systems and is threatening progress 
made by national TB control programs. The new 
Xpert Xpress SARS-CoV-2 test is run on the same 
GeneXpert instruments as those for Xpert MTB/RIF 
and Ultra testing; it is being expedited for large-scale 
production and deployment. Consequently, TB-test-
ing capacity, already limited by the availability of 
necessary staff, testing modules, and Xpert MTB/RIF 
and Ultra cartridges, may be further reduced by the 
increased demand for GeneXpert for COVID-19 test-
ing (3). There is an urgent need to develop laboratory 
testing approaches to expand TB diagnostic and case-
finding services in preparation for crises, such as the 
COVID-19 pandemic. 
GeneXpert-based testing for TB requires 1 car-
tridge per sputum sample. However, screening for 
other infectious diseases has used sample pooling 
methods, in which samples from several patients are 
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GeneXpert-based testing with Xpert MTB/RIF or Ultra 
assays is essential for tuberculosis diagnosis. However, 
testing may be affected by cartridge and staff shortages. 
More efficient testing strategies could help, especially dur-
ing the coronavirus disease pandemic. We searched the 
literature to systematically review whether GeneXpert-
based testing of pooled sputum samples achieves sensi-
tivity and specificity similar to testing individual samples; 
this method could potentially save time and preserve 
the limited supply of cartridges. From 6 publications, we 
found 2-sample pools using Xpert MTB/RIF had 87.5% 
and 96.0% sensitivity (average sensitivity 94%; 95% CI 
89.0%–98.0%) (2 studies). Four-sample pools averaged 
91% sensitivity with Xpert MTB/RIF (2 studies) and 98% 
with Ultra (2 studies); combining >4 samples resulted 
in lower sensitivity. Two studies reported that pooling 
achieved 99%–100% specificity and 27%–31% in car-
tridge savings. Our results show that pooling may improve 
efficiency of GeneXpert-based testing. 
SYNOPSIS
pooled together for a single test to optimize process-
ing. If a pooled-sample test is negative, all samples in 
the pool are considered negative; if the pooled-sam-
ple test is positive, all samples in the pool are retested 
individually to identify the samples that are positive. 
This method is routinely used in situations where the 
prevalence of disease is low (e.g., blood banks screen-
ing donated blood for hepatitis and syphilis) (4–9). 
The method can substantially reduce workload and 
cost and, for TB, could more efficiently process sam-
ples for diagnosis. We reviewed the literature to de-
termine the accuracy of pooling for Xpert MTB/RIF 
and Ultra detection of pulmonary TB, with the aim 
of supporting TB programs as they continue to test 
for TB in the context of increased resource constraints 
during the COVID-19 pandemic. 
Methods 
We conducted a systematic review following the 
Cochrane Collaboration’s Diagnosis Test Accuracy 
Working Group protocol (https://methods.cochrane.
org). Our primary aim was to describe whether test-
ing using GeneXpert for pulmonary TB on pooled 
samples would result in similar numbers of patients 
being confirmed with TB as testing samples individu-
ally. Secondarily, we aimed to describe the advan-
tages and disadvantages reported, such as savings in 
cartridges used and time required to process samples. 
We searched PubMed, CINAHL, Global Health, 
and Web of Science for publications from Janu-
ary 2010–March 2020 with no regional or language 
restrictions. We used the terms “GeneXpert” OR 
“Xpert” OR “Ultra” AND “tuberculos*” AND “pool*” 
AND “diagnos*” with associated subject headings 
and search terms without filters (Appendix Table, 
https://wwwnc.cdc.gov/EID/article/27/3/20-
4090-App1.pdf). S.V.M.A.L. and K.K. eliminated du-
plicates, screened titles and abstracts, and read full 
texts to determine eligibility. We also searched for ar-
ticle references manually and for abstracts published 
at the 2019 Union World Conference of Lung Health. 
Studies were included if they presented original data, 
if data were not duplicated in other publications, and 
if the articles were not reviews or opinions. We ex-
cluded studies that pooled several samples from the 
same patient to increase the yield and those that in-
cluded samples other than sputum. Given the paucity 
of studies, we included both those that directly pro-
cessed patient samples and those that used leftover 
samples to prepare a specimen repository for bench 
evaluation of the pooling method. We read selected 
studies in full for data extraction; L.E.C. and V.S.S. re-
solved disagreements by consensus. 
Data extracted included study identifiers (au-
thor, year, country, and setting), methods (study 
design, pooling methods, number of participants, 
pooling ratio, number of pools, and type of test), and 
whether the pooled positive and negative test results 
coincided with those obtained through individual 
testing. Data are presented as sensitivity and speci-
ficity values, considering the individual GeneXpert 
test as the reference. Sensitivity was defined as the 
proportion of pooled samples correctly identified as 
positive when the pool contained at least 1 sample 
with a positive individual GeneXpert test. Specific-
ity was defined as the proportion of pooled samples 
correctly identified as negative when all samples 
in the pool were negative in individual GeneXpert 
tests. Data are presented with 95% confidence inter-
vals and ranges. 
We assessed the quality of the studies based on 
a further reference standard, the use of TB culture by 
any method, whether pooled results were recorded 
blind to the individual results and whether partici-
pants had been recruited consecutively to represent 
the range of disease severity. The quality of studies 
and the risk of bias were assessed by 2 independent 
reviewers (authors) using the QUADAS-2 (Quality As-
sessment of Diagnostic Accuracy Studies) guidelines 
(https://www.bristol.ac.uk/media-library/sites/
quadas/migrated/documents/quadas2.pdf). We used 
Cochrane Collaboration Rev-Man 5.3 software 
(https://training.cochrane.org/online-learning/core-
software-cochrane-reviews/revman/revman-5-down-
load) to generate the graphs on the risk of bias (Ap-
pendix Figures 1, 2). Because the studies were highly 
heterogeneous and most (4/6) did not present data on 
specificity, we were unable to perform a meta-analysis 
to estimate the pooled sensitivity and specificity or to 
explore the reasons for heterogeneity through meta-
regression. Institutional review board approval was 
not required because all data sources and publications 
were in the public domain and in aggregate format. 
Results 
We identified 33 publications through the initial pub-
lication search. After screening titles and abstracts, 
we assessed 5 full-text articles for eligibility and 
initially included 2 in data syntheses. In addition, 4 
studies were identified from other sources: 1 confer-
ence report, 1 preprint article, and 2 articles from the 
reference lists of other studies. We included 6 articles 
in the final data synthesis (Figure 1). One study was 
conducted in South America (10), 2 in Africa (11,12), 
and 3 in Asia (13–15); all were published during 2014–
2020, before the COVID-19 pandemic. 
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We assessed the quality of the studies and the 
risk of bias (Appendix Figures 1, 2). Three studies 
used samples collected directly from patients with 
presumptive TB, and 3 studies used previously col-
lected stored samples with known GeneXpert results. 
Studies pooling direct clinical samples were conduct-
ed in high-burden settings in which the proportion 
of patients that tested GeneXpert-positive was high 
(15%, 16%, and 38.6%), whereas stored samples were 
used to prepare pools varying the proportion of posi-
tive specimens in each pool to explore the effect on 
sensitivity. Pools were prepared with clinical samples 
from consecutive patients in 5 studies and in bench-
prepared spiked sputum in a laboratory setting in 1 
study. The latter study had also prepared the pool 
using combinations of smear-positive/culture-pos-
itive and smear-negative/culture-positive samples. 
Generally, the studies followed a similar approach to 
pooling: a sample was collected from patients with 
presumptive TB and split into aliquots for Xpert 
MTB/RIF or Ultra testing following the manufactur-
er’s guidelines. Studies that processed and homog-
enized sputum used the same steps for the individual 
and pooled GeneXpert tests. One aliquot was used to 
obtain an individual result, which was considered the 
reference result; and the second aliquot was mixed 
with aliquots from other patients and then tested as 
a pooled sample. All studies reported that laboratory 
technicians were blind to whether they were testing 
pooled versus individual samples. One study col-
lected smear and culture results from all participants 
in addition to the GeneXpert result (11). Four studies 
tested sputum using Xpert MTB/RIF (11–14) and 2 
with Ultra (10,15) (Table 1). 
These 6 studies tested 1,878 individual samples. 
Participants were recruited from hospitals (n = 262), 
ambulatory clinics (n = 914), and outreach activities 
(n = 702). The percentage of individual patients with 
Xpert MTB/RIF-positive tests included in the pools 
ranged from 8.9% to 37%, except for 1 in vitro study, 
which used spiked samples and prepared pools with 
up to 64% of positive samples. Only 15 (0.8%) par-
ticipants across all studies had rifampin resistance 
(Table 1). Overall, of the 690 pools tested, 117 pooled 
2 samples, 28 pooled 3 samples, 364 pooled 4 samples, 
37 pooled 5 samples, 16 pooled 6 samples, 36 pooled 8 
samples, 16 pooled 10 samples, 36 pooled 12 samples, 
and 40 pooled 16 samples. Most of the pools with high 
numbers of samples (≥6) per pool were in the bench-
based study. Only 2 studies reported specificity, 1 in 
which pools were tested with Xpert MTB/RIF (99%, 
95% CI 94%–100%) and 1 in which pools were tested 
with Ultra (100%, 95% CI 96%–100%; Table 2) (12,15). 
The 2 studies (13,14) combining 2 sputum sam-
ples per pool reported 87.5% and 96.0% Xpert MTB/
RIF sensitivity relative to individual testing (Figure 
2, panel A). The 4 studies combining 4 samples per 
pool reported sensitivities of 88% (10) and 96% (12) 
for Xpert MTB/RIF and 95% (13) and 100% (15) for 
Ultra (Figure 2, panel B). In 2 studies (10,13), pools 
combining >4 sputum samples reported lower sensi-
tivity ranges for Xpert MTB/RIF (63%–81%) and for 
Ultra (80%–100%) (Table 2). 
Given that all studies had <200 pools, we com-
bined the results from all studies with similar pool siz-
es and test type (e.g., all studies that pooled 4 samples 
and test them using Xpert MTB/RIF) to evaluate the ef-
fect of the number of pooled samples on accuracy. Al-
though this approach has limitations due to variations 
in study design and proportion of sample positivity, 
we believe the benefit of this preliminary analysis of 
the potential use of pooling during the COVID-19 pan-
demic outweighs these limitations. After combination, 
when using Xpert MTB/RIF, 114/117 2-sputa pools 
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Figure 1. Flow diagram of study selection for a systematic review 
of pooling sputum as an efficient method for Xpert MTB/RIF and 
Ultra (Cepheid, https://www.cepheid.com) testing for tuberculosis 
during the coronavirus disease pandemic.
SYNOPSIS
and 101/201 4-sputa pools tested contained an Xpert 
MTB/RIF-positive sputum; when using Ultra, 93/173 
4-sputa pools tested contained an Ultra-positive spu-
tum. If only pools containing a positive sputum sam-
ple were considered, 109/114 2-sputa pools tested by 
Xpert MTB/RIF had a MTB-positive result (sensitivity 
93.2%, 95% CI 87.0%–96.4%), and 94/101 4-sputa pools 
tested by Xpert MTB/RIF had a MTB-positive result 
(sensitivity 93.0%, 95% CI 86.4%–96.6%). Lastly, 92/93 
of the 4-sputa pools tested by Ultra had an MTB-pos-
itive result (sensitivity 98.9%, 95% CI 94.1%–99.9%), 
an increase in sensitivity over those tested by Xpert 
MTB/RIF. 
Studies reported slight changes in the cycle 
threshold (Ct) values of the pooled samples compared 
with the individual tests. Most of the Ct changes were 
relatively small, although studies were not sufficient-
ly powered to determine statistical significance. One 
study reported that the pooled Xpert MTB/RIF test 
was negative in 5/10 samples with very low indi-
vidual Xpert MTB/RIF semiquantitative results (12). 
The South African study that used reconstituted pro-
cessed sputa to generate pools reported that 20 pools 
containing 1 smear-positive and 4 smear-negative, 
but culture-positive, samples yielded a median Xpert 
MTB/RIF Ct value increase of 12 (IQR 0.3–20.0), and 
22 pools containing only smear-negative/culture-
positive samples had a median Ct increase of 6.2 (IQR 
3.2–16.0) (11). Another study (13) also reported that 
Xpert MTB/RIF Ct values increased slightly with in-
creasing pool ratios and, although most pools had Ct 
values similar to the individual sample tests, pools 
containing >12 sputum samples had a median in-
crease in Ct value of 2.1 (IQR 0.0–4.5). 
A study from South Africa (11) reported 5 five-
sample pools in which 1 was smear-positive/culture-
positive and RIF-resistant and 3 five-sample pools in 
which 1 was smear-negative/culture-positive and RIF-
resistant. All 8 pools containing RIF-resistant samples 
tested positive for RIF-resistance (11). However, in 
Chry et al. (15), of the 3 MTB-positive/RIF-resistant 
samples subjected to Ultra testing, the pools containing 
the samples yielded MTB-positive but RIF-sensitive re-
sults. Abdurrahman et al. (12) included MTB-positive/
RIF-resistant samples in all 4 pools, of which 3 were 
detected by Xpert MTB/RIF as MTB-positive/RIF-re-
sistant and 1 as MTB-positive/RIF-sensitive. 
Only 2 studies (12–15) reported on the operation-
al effects of using a pooling method, including car-
tridge costs and time savings. The 2 studies (12,15) us-
ing 4 samples per pool reported savings in cartridge 
costs alone of 31% ($2,295 on 230 Xpert MTB/RIF 
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Table 1. Characteristics of the studies, number of participants, and pool size used in a systematic review of pooling sputum as an 

























100 Yes MTB/RIF 1:5 20 20 (20.6) 80 (79.4) 5 Culture and 
SM pos 
   85   1:5 17 17 (20) 68 (32) 3 Culture 
pos/SM neg 




(13) Vietnam SS 118 No MTB/RIF 1:2 16 75 (63.6) 43 (36.4) NR None 
      1:4 16     
      1:6 16     
      1:8 16     
      1:10 16     
      1:12 16     
(14) Vietnam Hospitals 262 No MTB/RIF 1:2 101§ 99 (37.7) 163 (62.3) NR Pools 
constructed 1 
pos/1 neg 
(15) Cambodia ACF 584 No ULTRA 1:4 125 91 (15.6) 493 (84.4) 3 Used chest 
radiograph to 
screen 
      1:3 28    
(10) Brazil Prisons, SS 1,120 Yes ULTRA 1:4 20 100 (8.9) 1,020 (91.1) NR None 
      1:8 20     
      1:12 20     
      1:16 40     
*Xpert MTB/RIF and Ultra, Cepheid (https://www.cepheid.com). ACF, active case finding; GX, GeneXpert; hosp, hospitalized patients; neg, negative; NR, 
not reported; OPD, outpatient department; pos, positive; RIF, rifampin; SM, smear; SS, spiked samples. 
†Single tests. 
‡3 had failed results. 
§2 had failed results. 
 
 Pooling Sputum for TB Testing during COVID-19 
cartridges) and 27% ($2,092 on 202 Ultra cartridges). 
These 2 studies also reported reductions of 377 (62%) 
and 226 (26%) hours in the staff time required to pro-
cess and run samples (Table 3). All 6 studies includ-
ed comments indicating the pooling procedure was 
feasible and beneficial. The study from South Africa 
(11) noted the lower sensitivity found among smear-
negative/culture-positive patients. Several studies 
mentioned the need for specific training on the pool-
ing procedure. The only negative effect, reported 
anecdotally, was the need to process samples more 
carefully to avoid handling and reporting errors. No 
studies included data on patient outcomes, such as 
treatment initiation.
Discussion 
This systematic review synthesizes the available lit-
erature on the performance of the pooling method 
using sputum for GeneXpert testing for detecting pul-
monary TB. Although the number of studies is small, 
the studies reported high sensitivity and specificity 
for 1:2 and 1:4 pooling ratios, replicating single test 
results, but pooling >4 samples decreased sensitivity. 
Studies reporting Ct values consistently reported a 
slight increase in Ct values and corresponding lower 
MTB/RIF semiquantitative results for pooled sam-
ples. This result is to be expected because testing sam-
ples together necessarily dilutes individual samples. 
Efficiency gained by pooling samples could increase 
the resilience of TB diagnostic services in a time when 
health system resources are being challenged by the 
COVID-19 pandemic. 
The Xpert MTB/RIF Ultra cartridge was expect-
ed to help improve the sensitivity of pooled tests be-
cause the new assay has a much lower limit for de-
tection than Xpert MTB/RIF (16). Ultra’s improved 
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Table 2. Tuberculosis Xpert results of pools composed of positive and negative samples, with sensitivity and specificity, in a 
systematic review of pooling sputum as an efficient method for Xpert MTB/RIF and Ultra testing for tuberculosis during the coronavirus 
disease pandemic 
Study Pooling ratio 
Test results, no. Sensitivity, 
% (95% CI) 
Specificity, 
% (95% CI) True pos† False pos‡ False neg† True neg‡ 
(11) 1:5 (Cult neg/SM pos) 20 NA 0 NA 100 (80–100) NR 
 1:5 (Cult pos/SM neg) 13 NA 4 NA 76 (50–92) NR 
(12) 1:4 80 1 5 96 94 (87–98) 99 (94–100) 
(13) 1:2 14 NA 2 NA 88 (62–98) NR 
 1:4 14 NA 2 NA 88 (62–98) NR 
 1:6 11 NA 5 NA 69 (41–98) NR 
 1:8 10 NA 6 NA 63 (35–85) NR 
  1:10 13 NA 3 NA 81 (54–96) NR 
 1:12 13 NA 3 NA 81 (54–96) NR 
(14) 1:2 95 NA 4 NA 96 (90–99) NR 
(15) 1:4 73 0 0 80 100 (95–100) 100 (96–100) 
(10) 1:4 19 NA 1 NA 95 (75–100) NR 
 1:8 20 NA 0 NA 100 (83–100) NR 
 1:12 16 NA 4 NA 80 (56–94) NR 
 1:16 39 0 1 0 98 (87–100) NR 
*Xpert MTB/RIF and Ultra, Cepheid (https://www.cepheid.com). Cult, culture, NA, not applicable; neg, negative; NR, not reported; pos, positive;  
SM, smear. 
†At least one of the patients included in the pool had an Xpert-positive test. 
‡All patients included in the pool were Xpert-negative in the individual tests.  
 
Figure 2. Sensitivity and specificity for pooling sputum in the ratio of 1:2 (A) and pooling sputum in the ratio of 1:4 (B) in a systematic 
review of pooling sputum as an efficient method for Xpert MTB/RIF and Ultra testing (Cepheid, https://www.cepheid.com) for 
tuberculosis during the coronavirus disease pandemic.
SYNOPSIS
performance was confirmed by the higher sensitivi-
ties reported in 2 studies included in this review, sug-
gesting that Ultra may be preferred over Xpert MTB/
RIF for pooled sample testing (10,15). Moreover, the 
only 2 studies reporting specificity (of 99% and 100%) 
indicated that almost all pools containing all nega-
tive individual samples correctly reported negative 
results for the pooled samples (12–15). This is an im-
portant consideration because the additional steps 
required to split sputum samples and the need to 
keep track of sputum batches with a link between in-
dividual samples could be prone to cross contamina-
tion and error. Further studies are needed to replicate 
these findings under operational conditions. 
Regarding the reproducibility of RIF resistance re-
sults in pooled samples, in 1 study from South Africa, 
all 8 individual RIF-resistant results were detected as 
pooled RIF-resistant (11). However, in a study in Cam-
bodia, 3 samples with RIF-resistant results from indi-
vidual testing were reported as RIF-susceptible in the 
pooled testing (15) and in a study from Nigeria, pooling 
missed 1 of 4 RIF-resistant results (12). Although pool-
ing seems to be an unreliable method to detect RIF resis-
tance, in practice all samples from MTB-positive pools 
would be retested individually, which should replicate 
RIF resistance results from individual samples. 
Almost all studies reported anecdotal positive 
feedback from laboratory staff, and 2 studies (12,15) 
quantified savings in cartridge costs and staff time 
required to process samples. Although both of those 
studies reported substantial savings, they were 
conducted in populations with a high proportion 
of patients testing positive. If a high proportion of 
presumptive TB patients is expected to be positive, 
presumably a greater proportion of pools would test 
positive and require follow-up testing of individual 
samples. Savings therefore would be more substantial 
when applied within outreach case-finding activities 
in the community, where typically around 5% of sam-
ples are Xpert MTB/RIF-positive (12) and lower in 
referral and congregate centers (e.g., prisons), where 
patients might have a higher probability of having 
TB. The expected proportion of positive samples may 
therefore guide the pooling ratio selected for evalua-
tion. For example, in active case finding, it is likely a 
pool ratio of 1:4 would be highly efficient and gener-
ate substantial savings, whereas a ratio of 1:2 would 
be more suitable for busy TB diagnostic centers where 
the proportion of samples that are positive can be as 
high as 15%. Pooling is not likely to be useful at a 
much higher prevalence than 20%, because most of 
the pools would be positive and samples would have 
to be retested individually (B.G. Williams, unpub. 
data, https://arxiv.org/abs/1007.4903). Moreover, 
there are operational issues that need further study, 
as it is unclear whether the timing of sputum splitting 
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Table 3. Potential cost and time savings and positive and negative effects of pooling in a systematic review of pooling sputum as an 
efficient method for Xpert MTB/RIF and Ultra testing for tuberculosis during the coronavirus disease pandemic* 
Study Cartridge savings Time savings, h (%) Negative effects Positive effects 
(11) Model of 1,000 patients with 
TB prevalence rate of 3% 
found 67.5% cartridge 
savings 





Processes higher volume of samples with 
fewer materials; time savings 
(12) 11% cartridge savings for 
hospital-based patients 
377 (62%) Steps involved heighten 
potential for errors 
High-level agreement with individual Xpert 
results at reduced cost; substantial time 
savings to process hospital samples 
 41% cartridge savings for 
patients identified through 
active case finding 
NR NR Higher savings on cartridge cost and 
processing time for patients identified 
through active case finding 
(13) NR NR NR Improved feasibility and cost-effectiveness 
of large-scale testing; reduced  
number of cartridges 
(14) NR NR Increase in “error” results 
when using less buffer for 
pooling compared with 
standard buffer technique 
Reduced costs and number of cartridges 
(15) 27% (lower savings estimate 
using combination of 
approaches) 
226/876 (26%) for 
all samples; 300/876 
(30%) if hybrid 
approach used 
NR Method feasible; potential to reduce  
costs, increase throughput. Pooling can be 
used selectively if another screening test 
(e.g., radiograph) used for additional 
savings (hybrid approach) 
 34.5% (if used in patients 
with normal chest x-rays) 
NR NR Higher savings if only samples from  
patients without abnormal chest radiographs 
are included 
(10) NR NR NR Method sensitive and cost-effective 
*NR, not reported. 
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could affect results. For example, splitting samples 
before adding the GeneXpert buffers requires divid-
ing thick and infectious samples, which are likely to 
have unevenly distributed bacilli, whereas splitting 
after adding the buffers could increase the risk of 
cross contamination but provide a safer and more liq-
uid sample with more evenly distributed bacilli. 
To inform national programs, further research is 
needed to determine the effects on time savings from 
pooled testing, from sample collection to notification 
and treatment initiation. Two studies quantified large 
reductions in testing time from pooling (12,15), which 
could shorten turnaround times for patient notifica-
tion, but time to notification was not reported in any 
of the studies. Quality management of the pooling 
process is critical, as reflected in discussions in the 
studies highlighting the importance of sample man-
agement and procedure training. As with routine test-
ing procedures, ensuring that pooling is implemented 
in a biosafe and quality-assured manner would help 
mitigate risk to laboratorians from increased sample 
manipulation and prevent errors in sample handling 
and testing, which could reduce efficiency and benefit 
to both patients and programs. 
Our findings are especially relevant during the 
ongoing global COVID-19 pandemic, which is severe-
ly disrupting health services, the availability of diag-
nostic and treatment resources, supply chains, and 
other disease control efforts. Although the diagnosis 
of COVID-19 takes precedence, steps can be taken to 
preserve key services for diagnosing and treating pa-
tients with presumptive TB. Quarantine and restric-
tion of movement during the pandemic have limited 
accessibility to services and reduced the numbers 
of patients attending TB diagnostic and treatment 
centers. Confinement of the population to house-
holds and the resulting increase in contact with other 
household members in crowded conditions could in-
crease TB transmission. A surge in undetected cases, 
together with increases in treatment interruptions, 
will likely lead to increases in incident cases. Demand 
for testing also may cause severe resource constraints. 
Preparing for this scenario, such as by introducing 
pooling strategies, may result in more efficient use of 
limited resources. 
Before the COVID-19 pandemic, the World 
Health Organization issued guidelines promoting a 
rapid diagnostic test, such as a GeneXpert-based test, 
for all persons with presumptive TB (17). However, 
<20% of the GeneXpert TB tests necessary to test the 
estimated 100 million people who develop presump-
tive TB each year have been procured (2). Individual 
rapid molecular diagnostic testing for all patients 
with presumptive TB remains the standard of care 
and a goal for national TB programs worldwide, but 
the cost of individually testing all estimated symp-
tomatic persons using GeneXpert would have been 
more than US $1 billion in cartridges alone in 2018 
(2), more than the total amount of funding provided 
by international donors globally for TB in 2019 (18). 
Moreover, although passive case finding has long 
been the standard approach in many countries, it is 
becoming apparent that outreach beyond health fa-
cilities is needed to identify those with TB missed by 
programs (19). Increasing outreach activities usually 
means more testing, requiring more cartridges, will 
be needed. However, a typically greater negative-to-
positive testing ratio in persons identified through 
outreach activities means that pooling strategies 
might decrease costs. 
Despite the potential usefulness of our find-
ings, the quality of evidence we present remains in-
sufficient to support wide adoption of the pooling 
method. Because the 6 studies were heterogeneous, 
we were unable to conduct a meta-analysis, and we 
considered all the studies together with bench evalu-
ations of the technical sensitivity and specificity of the 
methods; our findings should therefore be considered 
hypothesis-generating to promote and inform further 
studies. Moreover, all studies were underpowered 
for investigating the performance of the pooled test-
ing method in subpopulations (e.g., HIV-positive vs. 
HIV-negative, men vs. women), and very few sam-
ples tested rifampin resistant. Ct values also need to 
be interpreted with caution. 
Although both Xpert MTB/RIF and Ultra tests re-
port Ct values, the test algorithms that determine their 
Ct and semiquantitative results differ, which impacts 
the interpretation of Ct-based analyses. Moreover, 
because Ct ranges vary between multiple tests on the 
same homogenized sample, it would have been pref-
erable to describe changes in positivity relative to the 
semiquantitative results. However, semiquantitative 
results were not reported in most studies. Similarly, 
although culture was used in some of the studies, 
this information was not used to stratify analyses. A 
second reference method would have been useful to 
further investigate whether discordant results were 
potentially due to improper sample management, 
cross-contamination in the laboratory, or random 
variation due to the bacilli not being homogeneously 
distributed in the sputum sample. 
Despite these limitations, we propose that the 
pooling method be considered as an interim option to 
strengthen capacity of TB laboratories during times of 
crisis, such as during the COVID-19 pandemic. Our 
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team is currently conducting accelerated evaluations 
of the pooling method in Laos and Nigeria. We en-
courage the TB community to conduct studies on the 
pooling strategy and other resource-saving strategies 
for TB diagnostic testing that generates data for open 
access databases to inform national programs. 
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